Clinical Readiness Lycia is moving into the clinic with its LYTAC-based protein degradation platform, supported by substantial funding and a new chief medical officer. This indicates momentum in clinical development and a readiness to engage in strategic partnerships to de-risk and accelerate programs in autoimmune and inflammatory diseases.

Undruggable Targets The platform targets extracellular proteins for lysosomal degradation, addressing targets outside the cell that are often undruggable with conventional modalities. This presents a clear route for pharma partners seeking to access new disease targets in autoimmune conditions, via licensing or co-development of LYTAC-enabled programs.

Strategic Partnerships Lycia has prior collaboration experience with Nona Biosciences and with Eli Lilly, plus successful fundraising, demonstrating a track record of BD activity and credibility. Use this history to structure milestone-based licensing, option rights, or strategic collaborations that align with clinical timelines.

Funding Runway The company reports meaningful funding with a runway that supports early development and deal exploration, alongside potential needs for manufacturing, process development, and regulatory readiness as programs advance. This creates opportunities to offer integrated development partnerships, including discovery licensing, contract development and manufacturing, and regulatory support packages.

Biotech Hub Based in South San Francisco, Lycia sits in a vibrant life sciences ecosystem with access to CROs, contract manufacturers, and potential US-based partners. This geographic proximity can accelerate partner outreach to autoimmune programs and enable rapid co-development conversations.